Safety and Efficacy of Bendamustine-Rituximab in Treatment Naïve Symptomatic Follicular Lymphoma: An Institutional Analysis

Indian Journal of Hematology and Blood Transfusion volume 37, pages169–170(2021)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

References

  1. 1.

    Fowler NH, Davis RE, Rawal S et al (2014) Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15:1311–1318

    CAS  Article  Google Scholar 

  2. 2.

    Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944–2952

    CAS  Article  Google Scholar 

  3. 3.

    Gogia A, Raina V, Kumar L et al (2017) Follicular lymphoma: an Institutional analysis. Asian Pac J Cancer Prev. 18:681–685

    PubMed  PubMed Central  Google Scholar 

  4. 4.

    Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label multicentre, randomized, phase 3 noninferiority trial. Lancet 381:1203–1210

    CAS  Article  Google Scholar 

  5. 5.

    Mondello P, Steiner N, Willenbacher W et al (2018) Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a multicentre, retrospective study. Oncologist 23:454–460

    CAS  Article  Google Scholar 

  6. 6.

    Morschhauser F, Fowler NH, Feugier P et al (2018) Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 379:934–947

    CAS  Article  Google Scholar 

  7. 7.

    Alamdari HS, Pinter-Brown L, Cassarino DS, Chiu MW (2010) Severe cutaneous interface drug eruption associated with bendamustine. Dermatol Online J 16(7):1

    PubMed  Google Scholar 

Download references

Funding

No funding received for the study.

Author information

Affiliations

  1. Department of Medical Oncology, Room No 218, Branch, All India Institute of Medical Sciences, New Delhi, India

    Ajay Gogia, Sudhir Kumar, Lalit Kumar & Atul Sharma

  2. Department of Pathology, All India Institute of Medical Sciences, New Delhi, India

    Soumya Mallick

Authors
  1. Ajay Gogia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sudhir Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lalit Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atul Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soumya Mallick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ajay Gogia.

Ethics declarations

Conflict of Interest

There is no conflict of interests for all 5 authors.

Ethical Approval

The study is in compliance with ethical standards. Institute ethical clearance was obtained for the retrospective study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gogia, A., Kumar, S., Kumar, L. et al. Safety and Efficacy of Bendamustine-Rituximab in Treatment Naïve Symptomatic Follicular Lymphoma: An Institutional Analysis. Indian J Hematol Blood Transfus 37, 169–170 (2021). https://doi.org/10.1007/s12288-020-01294-9

Download citation